CClinicalTrials.gg
RecruitingNCT04527445Updated Mar 6, 2026

Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement

An interventional study of Reduced radiation fluoroscopy and Conventional fluoroscopy in Radiation Exposure, Overactive Bladder and Urge Incontinence, sponsored by Loma Linda University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Loma Linda University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

Fluoroscopy is performed when placing a lead during a sacral neuromodulation procedure. During lead placement, subjects will receive either conventional or experimental fluoroscopic settings. The radiation exposure will be compared between the two groups.

Read the detailed description

Patients scheduled for lead implantation during sacral neuromodulation in the operating room and consent will be included in this study. Placement of the lead in the operating room with fluoroscopy is the standard of care in this procedure. Fluoroscopy is performed with a C-arm and there are settings that change the radiation exposure. Patients scheduled to undergo lead placement will be randomized to: a) the investigational (reduced radiation with fluoroscopic settings) or b. the control (conventional fluoroscopy).

The surgeon can change fluoroscopy radiation exposure by changing C-arm settings from the reduced radiation to conventional fluoroscopic options. During the surgery, the surgeon may change the settings from reduced radiation (intervention) to conventional fluoroscopy (control) to safely place lead. The surgeon will use their judgment to optimally place lead and maintain safety during placement. Any deviation from randomization will be recorded.

The intervention arm is defined: Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.

The control arm is defined: The standard of care in the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set at the default.

02

Conditions studied

  • Radiation Exposure
  • Overactive Bladder
  • Urge Incontinence
  • Urgency-frequency Syndrome

Keywords

  • Sacral Neuromodulation
  • Fluoroscopy
03

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients undergoing lead implantation for sacral neuromodulation that have overactive bladder as defined by urinary urgency, frequency, nocturia with or without urgency incontinence.

Exclusion criteria

Exclusion Criteria:

  • neurogenic bladder, BMI >40, or peripheral neuropathy.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Reduced Radiation Fluoroscopy

    Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.

    Procedure: Reduced radiation fluoroscopy

  • Active comparator
    Conventional Fluoroscopy

    The standard of care is the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set as the default.

    Procedure: Conventional fluoroscopy

Interventions

  • ProcedureReduced radiation fluoroscopy

    See previous information about each arm

  • ProcedureConventional fluoroscopy

    See previous information about each arm

05

What researchers measure

Primary outcomes

  1. Radiation Exposure

    measure radiation exposure, milligray (mGy)

    Time frame: At time of procedure

Secondary outcomes

  1. Optimal lead placement

    based on intraoperative motor response

    Time frame: At time of procedure

  2. Voiding log (Bladder Record)

    Clinical Outcome

    Time frame: 3 months after surgery

  3. Clinical Outcome assessed by validated questionnaire

    Time frame: 3 months after surgery

  4. Inoperative complications

    surgery complication

    Time frame: At time of procedure

  5. Operative times

    minutes

    Time frame: At time of procedure

06

Study locations

1 of 1 sites recruiting
  • Loma Linda University Health
    Loma Linda, California 92354, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04527445
Lead sponsor
Loma Linda University
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Forrest Jellison, MD
Contact
fjellison@llu.edu
909 558-2830
Forrest Jellison, MD
principal investigator · Loma Linda University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion